Novavax has signed an agreement with the US Department of Health and Human Services (HHS), in partnership with the Department of Defense, under which the US government will procure 3.2 million doses of the company’s Covid-19 vaccine, NVX-CoV2373, in the initial stage.

The order is contingent on the vaccine obtaining Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) as well as the Centers for Disease Control and Prevention (CDC) recommendation. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A protein-based vaccine, NVX-CoV2373 is created from the genetic sequence of the SARS-CoV-2 virus’ initial strain.

It is formulated with the company’s saponin-based Matrix-M and also comprises a purified protein antigen.

Following authorisation, the vaccine will be offered for free to jurisdictions, states, federal pharmacy partners and health centres that are federally qualified.

In June this year, the Vaccines and Related Biological Products Advisory Committee of the FDA voted to recommend granting an FDA EUA for the vaccine in people aged 18 years and above. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Presently, the EUA application for the vaccine submitted by the company is being reviewed by the FDA. 

Novavax president and CEO Stanley Erck said: “We are pleased to come one step closer to potentially offering our vaccine to physicians, healthcare organisations, and consumers who have been awaiting a protein-based vaccine option. 

“We are grateful for the US Government’s ongoing support and partnership to bring Novavax’s Covid-19 vaccine to the US, and we look forward to the FDA’s decision on an emergency use authorization.”

Last week, the European Commission approved the expanded conditional marketing authorization for Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union for use in adolescents aged 12 to 17 years.